Similarly, the monocyte shift toward M2/CD163+ TAMs by increased levels of M-CSF has been seen in other tumor types such as glioma [41], clear cell renal carcinoma [42], ovarian carcinoma [43] and a mouse model of osteosarcoma [44]. This evidence concerns the gene CD163 and central nervous system cancer.